Vaccine Characterization Using Advanced Technology - Mass spectrometry offers the potential for an unprecedented understanding of vaccines and why they fail. - BioPharm International

ADVERTISEMENT

Vaccine Characterization Using Advanced Technology
Mass spectrometry offers the potential for an unprecedented understanding of vaccines and why they fail.


BioPharm International


Vaccine Characterization

Vaccine Characterization Using Classical Methods

The classical methods of vaccine characterization rely on the study of physical-chemical properties using methods such as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), pH, various stress conditions (agitation, freeze-thaw, etc.) based on particulate formation, and methods of quantitating protein content as well as elemental composition. While these methods are capable of determining whether or not the end product is consistent with previous batches, they are unable to detect small changes that can result in a vaccine with reduced or even lost preventative characteristics. Not all changes to the structure of the vaccine components have physical consequences, but many of them result in reduced vaccine performance. Most of these techniques lack sensitivity when it comes to detecting small changes in the structure of the vaccine components that can cause them to fail during use. Some changes can cause severe side reactions even in small quantities.

TGA and DSC are used to analyze the denaturing point of the vaccine protein or nucleotide. These tests generally give indirect indications of changes in the vaccine with time and stress. Changes in protein sequence or modifications can substantially affect denaturing kinetics, but these techniques provide no way to correlate these changes with actual changes in the structure of the molecule. Appearance and pH are used to monitor major changes in the composition of the vaccines and are relatively insensitive to these changes. Other physical characteristics that affect vaccine function include particle size and particle size distribution. Clumping of the vaccine antigen can degrade the function of the vaccine and can cause unwanted side effects. Specific tests for quantitating proteins or oligonucleotides, such as elemental analysis and total protein content (bicinchoninic acid, or BCA) tests, can provide vital quality control data for troubleshooting manufacturing problems, but they are of limited value in analyzing degradation of the vaccines since elemental composition changes from degradants represent only a small percentage of the overall elemental composition. In addition, most protein degradants will still be identified as proteins in a total protein analysis. The conditions used for these assays also break up clumped proteins or oligonucleotides and are insensitive to most changes caused by minor structural modifications of these molecules.

Vaccine Characterization Using Mass Spectrometry Technologies

Various mass spectrometry (MS) technologies are readily available today for use in vaccine characterization to assist in understanding vaccine properties and functions for all phases of vaccine development processes from vaccine discovery, development, formulation, manufacturing, stability, QC, and release, to post-market surveillance. ICPMS, GC–MS, HPLC–MS, and ESI–Q-ToF–MS are a few of the MS technologies that can be used extensively in vaccine characterization.

ICP–MS is used to qualitatively and quantitatively measure toxic metals that can be introduced into a vaccine by the manufacturing process and can have severe negative effects when the vaccine goes into widespread use. The ICP–MS technique oxidizes all of the organic components in the vaccine to CO2, leaving behind all of the metal ions to be analyzed by either hot or cold plasma mass spectrometry. The results obtained from ICP-MS analysis can provide some insights into loss of metal co-factors and other groups.

GC–MS and HPLC–MS are used to determine the molecular weight of the various vaccine components. These technologies can provide a means of determining if a change in the molecular structure has occurred, but generally cannot localize it. Improvements in the sensitivity of mass spectrometers and the increasing mass accuracy of the instruments have improved the capabilities of these tests to the point where they can identify even minor changes in the vaccine components. Localizing these modifications relies on another feature of the mass spectrometer. By placing a collision cell between two mass analyzers, additional structural information can be obtained. In the case of proteins and oligonucleotides, these fragmentation events occur in a predictable manner that allows interpretation of even very complex spectra. With instruments possessing a high mass accuracy, localization of modifications to the protein can be accomplished. Many software packages currently available can automate this process substantially.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis and GSK Trade Assets
April 22, 2014
Lilly to Acquire Novartis Animal Health
April 22, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here